There’s still no vaccine for chlamydia. There’s still no vaccine for gonorrhea. Two of the most common bacterial STIs in the adult industry — the two that show up on basically every performer testing panel — and after decades of research, science hasn’t cracked either one.

That could soon change.

Eli Lilly announced yesterday it’s buying Swiss biotech LimmaTech Biologics for up to $780 million, part of a roughly $3.8 billion push into infectious disease vaccines. The reason that matters: LimmaTech happens to be sitting on two of the most promising early-stage vaccine programs in the world — one for gonorrhea, one for chlamydia.

You went to CET. You did your panel… and now you popped positive and are unable to shoot for weeks or more. It’s every performer’s nightmare.

PASS and most studio requirements run 14-day clearance after a clean test. A positive means time off set, treatment, contact tracing, and momentum gone. It happens more than people outside the business realize, even with strict protocols in place.

A vaccine that actually prevents these infections could cut those disruptions way down. Fewer positives mean more consistent shooting schedules, less stress about getting sidelined, and some real protection against long-term issues like infertility from chlamydia.

Of course, the development of these drugs is still in its early stages. Preclinical means human trials and actual approval are likely years away. But with Lilly’s resources now behind it, these programs could move faster than they would have otherwise.

The adult industry has been ahead of the curve on regular testing and prevention for years. Adding effective vaccines for the most common bacterial STIs would be the next logical step.

We’ll keep an eye on how this develops. If these candidates advance, it could quietly become one of the more important upgrades to performer health in a long time.

Would you get the shot if it becomes available?